加用基于六味地黄丸的中医药治疗2型糖尿病合并慢性肾脏病:一项多中心随机对照试验
这项多中心、评估者盲法、标准治疗对照的随机试验纳入148例2型糖尿病合并CKD、eGFR 30-90 ml/min per 1.73 m²且UACR 300-5000 mg/g的成人患者,1:1随机接受48周加用基于六味地黄丸的中医药方案或单用标准治疗。加用中医药组eGFR下降斜率较对照组少2.7 ml/min per 1.73 m²/年(95%CI 0.1至5.3;P=0.04),UACR变化组间差异未达统计学显著(P=0.28)。
要点
- 加用基于六味地黄丸的中医药治疗48周可稳定2型糖尿病合并CKD患者的eGFR。
- eGFR下降斜率组间差异为2.7 ml/min per 1.73 m²/年(95%CI 0.1至5.3;P=0.04)。
- UACR变化组间比例差异未达统计学显著(P=0.28)。
核心结论
- 在单用标准治疗基础上加用基于六味地黄丸的中医药治疗48周,可稳定2型糖尿病、CKD 2-3期且白蛋白尿严重增加患者的eGFR。
研究设计与样本
- 随机、评估者盲法、标准治疗对照、平行、多中心试验,纳入148例来自门诊的2型糖尿病成人患者,eGFR 30-90 ml/min per 1.73 m²且UACR 300-5000 mg/g,1:1随机接受48周加用方案化中医药治疗(基于六味地黄丸的颗粒剂口服)或单用标准治疗。
主要发现
- eGFR变化斜率在加用中医药组为-2.0(95%CI -0.1至-3.9)ml/min per 1.73 m²,单用标准治疗组为-4.7(95%CI -2.9至-6.5)ml/min per 1.73 m²,组间差异为加用中医药组少下降2.7 ml/min per 1.73 m²/年(95%CI 0.1至5.3;P=0.04)。
- UACR变化斜率估计比例在加用中医药组为0.88(95%CI 0.75至1.02),单用标准治疗组为0.99(95%CI 0.85至1.14),组间比例差异为0.89(加用中医药组增幅慢11%,95%CI 0.72至1.10;P=0.28),未达统计学显著。
- 50例参与者共记录85例不良事件,加用中医药组22例(31%) vs 对照组28例(36%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diabetes is the leading cause of CKD and kidney failure. We assessed the real-world effectiveness of Rehmannia-6-based Chinese medicine treatment, the most used Chinese medicine formulation, on the change in eGFR and albuminuria in patients with diabetes and CKD with severely increased albuminuria. METHODS: In this randomized, assessor-blind, standard care-controlled, parallel, multicenter trial, 148 adult patients from outpatient clinics with type 2 diabetes, an eGFR of 30-90 ml/min per 1.73 m 2 , and a urine albumin-to-creatinine ratio (UACR) of 300-5000 mg/g were randomized 1:1 to a 48-week add-on protocolized Chinese medicine treatment program (using Rehmannia-6-based formulations in the granule form taken orally) or standard care alone. Primary outcomes were the slope of change in eGFR and UACR between baseline and end point (48 weeks after randomization) in the intention-to-treat population. Secondary outcomes included safety and the change in biochemistry, biomarkers, and concomitant drug use. RESULTS: The mean age, eGFR, and UACR were 65 years, 56.7 ml/min per 1.73 m 2 , and 753 mg/g, respectively. Ninety-five percent ( n =141) of end point primary outcome measures were retrievable. For eGFR, the estimated slope of change was -2.0 (95% confidence interval [CI], -0.1 to -3.9) and -4.7 (95% CI, -2.9 to -6.5) ml/min per 1.73 m 2 in participants treated with add-on Chinese medicine or standard care alone, resulting in a 2.7 ml/min per 1.73 m 2 per year (95% CI, 0.1 to 5.3; P = 0.04) less decline with Chinese medicine. For UACR, the estimated proportion in the slope of change was 0.88 (95% CI, 0.75 to 1.02) and 0.99 (95% CI, 0.85 to 1.14) in participants treated with add-on Chinese medicine or standard care alone, respectively. The intergroup proportional difference (0.89, 11% slower increment in add-on Chinese medicine, 95% CI, 0.72 to 1.10; P = 0.28) did not reach statistical significance. Eighty-five adverse events were recorded from 50 participants (add-on Chinese medicine versus control: 22 [31%] versus 28 [36%]). CONCLUSIONS: Rehmannia-6-based Chinese medicine treatment stabilized eGFR on top of standard care alone after 48 weeks in patients with type 2 diabetes, stage 2-3 CKD, and severely increased albuminuria. CLINICAL TRIAL REGISTRY: Semi-individualized Chinese Medicine Treatment as an Adjuvant Management for Diabetic Nephropathy (SCHEMATIC), NCT02488252 .
引用
- Chan KW, Kwong ASK, Tan KCB, et al. Add-on Rehmannia-6-Based Chinese Medicine in Type 2 Diabetes and CKD: A Multicenter Randomized Controlled Trial. Clin J Am Soc Nephrol. 2023. PMID: 37307005. doi:10.2215/CJN.0000000000000199
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。